MedinGlobal

Edit Template

CYENDIV 150 MG

In Stock

CYENDIV 150 MG contains Nintedanib (150mg), an antifibrotic medicine belonging to the tyrosine kinase inhibitor class. It may be prescribed for idiopathic pulmonary fibrosis and other approved progressive fibrosing lung diseases. Selected oncology indications vary by jurisdiction. It works by inhibiting signaling pathways involved in fibrotic lung scarring. Treatment requires specialist supervision and appropriate monitoring.

Medinglobal provides product information and medicine enquiry coordination. Availability and any subsequent supply are subject to confirmation by an authorised independent provider and applicable regulations.

CYENDIV 150 MG – Composition, Uses and Medicine Enquiries

Product Overview

CYENDIV 150 MG is listed as a prescription product containing Nintedanib (150mg), marketed by Boehringer Ingelheim. It belongs to the antifibrotic and tyrosine kinase inhibitor class and may be prescribed for idiopathic pulmonary fibrosis and other approved progressive fibrosing lung diseases. Selected oncology indications vary by jurisdiction.

The active medicine inhibits signaling pathways involved in fibrotic lung scarring. Treatment suitability depends on the confirmed diagnosis, organ function, previous treatment and other medicines.

A qualified clinician should assess suitability, interactions, contraindications and monitoring requirements. Liver tests, diarrhea, bleeding risk and pregnancy precautions need attention.

Composition and Strength

Active Ingredient Strength
Nintedanib 150 mg

Product Name: CYENDIV 150 MG

Generic Name: Nintedanib

Brand Name: CYENDIV 150 MG

Strength: 150 mg

Listed Marketer: Boehringer Ingelheim

The exact manufacturer pack and product presentation should be verified against the original packaging and approved product information.

Therapeutic Category and Indication

CYENDIV 150 MG belongs to the antifibrotic medicine category and is classified as a tyrosine kinase inhibitor.

It may be used for idiopathic pulmonary fibrosis and other approved progressive fibrosing lung diseases. Selected oncology indications vary by jurisdiction.

Its active ingredient inhibits signaling pathways involved in fibrotic lung scarring.

The appropriate treatment choice, approved use and benefit-risk balance must be determined by the treating specialist.

Administration Information

CYENDIV 150 MG is listed as an oral soft gelatin capsule.

It should be taken with food and swallowed whole according to the prescribed schedule.

Patients should follow the treating clinician’s instructions and the approved product label. The dose should not be independently adjusted, and safety monitoring should not be skipped.

Patients should not switch formulations without medical advice.

Product Presentation and Availability

The product enquiry can be made using the following details:

  • Product Name: CYENDIV 150 MG
  • Generic Name: Nintedanib
  • Strength: 150 mg
  • Therapeutic Category: Antifibrotic
  • Medicine Class: Tyrosine Kinase Inhibitor
  • Manufacturer Listed: Boehringer Ingelheim
  • Dosage Form: Oral soft gelatin capsule

The exact dosage form, pack size, batch, storage, expiry and product-specific presentation must be verified from the original manufacturer packaging and an authorised provider.

Product details and supply eligibility may vary by country.

Prescription and Patient Safety

CYENDIV 150 MG is a prescription medicine that requires assessment and supervision by a qualified healthcare professional.

Treatment suitability depends on the confirmed diagnosis, organ function, previous treatment and other medicines.

Liver tests, diarrhea, bleeding risk and pregnancy precautions need attention. The treating specialist should determine the appropriate monitoring plan and assess potential interactions and contraindications.

Patients should follow the approved product label and should not independently change their prescribed treatment.

Medicine Enquiry Coordination Through Medinglobal

Medinglobal is a healthcare coordination platform. It can receive medicine information requests and, where legally permissible, connect patients or institutions with appropriately authorised independent pharmaceutical providers.

Medinglobal does not itself sell, dispense, manufacture or export CYENDIV 150 MG.

Product availability, lawful supply, prescription validation, commercial terms and destination requirements must be verified by the independent provider. Submitting an enquiry does not guarantee fulfilment.

How to Submit a CYENDIV 150 MG Enquiry

To help identify the requested product, include the following details:

  1. Product or brand name: CYENDIV 150 MG.
  2. Generic name: Nintedanib.
  3. Required strength and formulation.
  4. Required quantity.
  5. Destination country.
  6. Prescription or institutional documents, where required.

Medinglobal may coordinate an introduction to a suitably authorised provider, who independently verifies product details, regulatory eligibility and any transaction.

Frequently Asked Questions

What is CYENDIV 150 MG used for?

CYENDIV 150 MG may be used for idiopathic pulmonary fibrosis and other approved progressive fibrosing lung diseases. Selected oncology indications vary by jurisdiction. The prescriber confirms the approved use.

What is the composition of CYENDIV 150 MG?

The supplied product information lists Nintedanib 150 mg as its active ingredient.

How is CYENDIV 150 MG administered?

It is listed as an oral soft gelatin capsule taken with food. It should be swallowed whole according to the prescribed schedule.

Which company markets CYENDIV 150 MG?

The supplied product catalogue lists Boehringer Ingelheim.

What precautions are associated with CYENDIV 150 MG?

Liver tests, diarrhea, bleeding risk and pregnancy precautions need attention. Monitoring requirements should be determined by the treating specialist.

Can Medinglobal supply CYENDIV 150 MG directly?

No. Medinglobal coordinates medicine enquiries with independent authorised providers where legally permissible.

Product Name

Generic Name

Brand Name

Composition

Strength

Therapeutic Category

Medicine Class

Indication

Dosage Form

Route of Administration

Reviews

There are no reviews yet.

Be the first to review “CYENDIV 150 MG”

Your email address will not be published. Required fields are marked *

Pharmaceutical Disclaimer

Medinglobal Platform does not sell, dispense, manufacture or prescribe medicines. Pharmaceutical information on this page is provided solely for general information, product identification and enquiry coordination. Product listing is not medical advice, a recommendation or an offer for sale by Teji Radiance or the Medinglobal Partnership Firm. Prescription medicines require a valid prescription where applicable. Any regulated pharmaceutical activity is undertaken by the relevant independent provider subject to applicable law. Always consult an appropriately qualified healthcare professional before using or changing any medicine.

Scroll to Top